Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC raised its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 4.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 478,579 shares of the company's stock after buying an additional 21,539 shares during the quarter. Natixis Advisors LLC's holdings in Takeda Pharmaceutical were worth $6,336,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Avantax Advisory Services Inc. purchased a new stake in Takeda Pharmaceutical during the 4th quarter worth approximately $145,000. Farther Finance Advisors LLC increased its position in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after acquiring an additional 1,976 shares during the period. EverSource Wealth Advisors LLC raised its stake in Takeda Pharmaceutical by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock worth $69,000 after acquiring an additional 1,770 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in Takeda Pharmaceutical by 44.2% during the 4th quarter. Sequoia Financial Advisors LLC now owns 37,943 shares of the company's stock worth $502,000 after acquiring an additional 11,637 shares during the period. Finally, HighTower Advisors LLC grew its stake in Takeda Pharmaceutical by 1.5% during the 4th quarter. HighTower Advisors LLC now owns 124,439 shares of the company's stock valued at $1,648,000 after purchasing an additional 1,852 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Remove Ads

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK traded down $0.05 during trading on Wednesday, hitting $15.00. The stock had a trading volume of 1,578,187 shares, compared to its average volume of 1,794,727. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.31. The stock has a market capitalization of $47.71 billion, a price-to-earnings ratio of 37.49, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. The stock has a 50-day simple moving average of $14.04 and a two-hundred day simple moving average of $13.91.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.